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2ABSTRACT
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognos-
tic and predictive information. This study aims to assess the spatial and temporal heterogene-
ity of TILs in BC and its relationship with immune cell subtypes.
Method: Immunohistochemically-defined immune cell subtypes; T-cell markers (CD3, CD8,
and FOXP3), B-cell marker (CD20) and histiocytic marker (CD68) were evaluated in a large
series (n=1,165) of invasive BC. A subset of full-face haematoxylin and eosin (H&E) stained
slides were examined for TILs heterogeneity within primary tumours and the corresponding
local recurrent carcinomas to report on spatial and temporal TILs heterogeneity. H&E stained
sections from multiple tumour blocks (3-4 blocks per case) representing different tumour ar-
eas were evaluated to assess TILS inter-slide heterogeneity as well as intra-slide heterogene-
ity. Both average (AV-TILs) and hotspot (HS-TILs) stromal TILs were assessed.
Results: AV-TILs showed association with all immune cell subtypes however; the main com-
ponent were CD3+ cells (mean number = 55) whereas CD20+cells comprised the least com-
ponent (the mean number = 13). There was no significant statistical difference between TILs
across tumour blocks of the same case (p=0.251 for AV-TILs and p=0.162 for HS-TILs). Triple
negative breast cancer (TNBC) showed higher TILs compared with other BC subtypes
(p<0.001). High AV-TILs, CD3+, CD8+, and CD20+ cells were associated with longer sur-
vival in TNBC (p<0.05). High AV-TILs in recurrent tumours showed significant association
with shorter post-recurrence survival (p=0.004).
Conclusion: Despite the heterogeneity of immune cell type components, average TILs in one
full-face H&E stained section reliably represent whole tumour TILs. TILs were associated with
outcome in TNBC as well as provided prognostic significance in recurrent tumour.
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4INTRODUCTION
Breast cancer (BC) microenvironment comprises a complex mixture of cell types including
immune modulating cells that provide an opportunity for therapeutic modulation 1, 2. Several
studies have reported prognostic and predictive roles of tumour infiltrating lymphocytes (TILs)
in BC as assessed on haematoxylin and eosin (H&E) stained sections regardless of their cellular
subtypes 3-6 and guideline recommendations to standardise TILs assessment in BC have been
published 7. However, the impact of TILs heterogeneity, with variable TILs density and com-
ponents in different tumour areas within BC subtypes remains to be defined. Various TILs
subtypes have different roles in tumour progression either suppressing tumour growth by de-
stroying cancer cells or promoting tumour progression by selecting those tumour cells that
could survive in an immunocompetent host 8-10. For instance, T-lymphocytes, which account
for the majority of TILs in invasive BC, can activate host defense mechanisms 9 mainly through
cytotoxic CD8+ T-cells. However, T regulatory cells (T-reg) play a vital role in immune toler-
ance to tumour cells and can protect against tumour development and progression 10-12. The
contribution of each immune cell subtype to the prognostic value of overall TILs assessed on
H&E slides also remains unclear. In addition, the role of histiocytes, as a component of the
immune cells in BC, and whether they contribute prognostic value and should be included in
TILs assessment in BC has not been resolved.
This study aims to investigate i) the TILs infiltrate in invasive BC and its spatial distribution
and relate this to prognostic parameters and patient outcome in primary and recurrent tumours.
ii) Contribution of various immune cell subtypes, as molecularly defined, to overall TILs and
their prognostic value were also evaluated.
5MATERIALS AND METHODS
Study cohort
The study cohort comprised 1,165 invasive BCs derived from the retrospective Nottingham
Primary Breast Carcinoma Series of patients presenting to Nottingham City Hospital between
1988 to 1998. Immunohistochemical detection of a panel of T lymphocytes markers including
pan T-cell CD3, cytotoxic T-cell CD8, T-reg FOXP3, B-cell CD20, and Histiocytic cell
marker; CD68 were previously performed 13-15. Full-face H&E stained sections from a subset
of cases (n=230) were used to assess TILs infiltration as well as intra-slide heterogeneity.
Moreover, to assess inter-slide TILs heterogeneity, H&E stained slides from multiple formalin
fixed paraffin embedded (FFPE) archival tissue blocks (3-4 blocks/case) were prepared from a
sub-group of cases (n=52/230). Patients’ clinical and pathological data including age at presen-
tation, histological tumour type, primary tumour size, axillary lymph node status, histological
tumour type, Nottingham Prognostic Index (NPI), Lymphovascular Invasion (LVI) and adju-
vant chemotherapy were available. Biological data on expression of ER, PgR, HER2, EGFR,
androgen receptor (AR) and basal cytokeratins (CK5/6 and CK14) was also available 16, 17. The
data on HER2 was already available in this early-stage breast cancer cohort and details of
staining and scoring were included in previous publications20-23. Survival data was prospec-
tively maintained including 1) breast cancer-specific survival (BCSS), defined as the time (in
months) from the date of primary surgical treatment to the time of death from BC and 2) distant
metastasis free survival (DMFS), defined as the time from the surgery until the first event of
distant metastasis. In this study, post recurrence survival was defined as the time (in months)
from the date of surgical removal of the recurrent tumour to the date of death from BC. Of the
recurrent cases, 44 patients had a local recurrence tumour tissue available and these were used
to compare TILs distribution between primary and corresponding recurrent tumour.
6This study was approved by the Nottingham Research Ethics Committee 2 under the title “De-
velopment of a molecular genetic classification of breast cancer”.
Immunohistochemistry and Immunoscoring
The total number of each immune cell type and histiocyte were counted in the stroma surround-
ing the tumour in each core. Supplementary table 1 shows the details of the different antibodies
which were used.
TILs assessment on H&E stained sections
All tumour specimens were routinely fixed in 10% formalin and embedded in paraffin. Full-
face, 4µm sections were prepared for H&E staining and evaluated for stromal TILs. All cases
contained adequate tumour burden with at least 40% of the section surface area in each slide.
H&E slides were scanned into high-resolution digital images at 20x magnification using 3D
Histech Panoramic 250 Flash II scanner (3DHISTECH Ltd., Budapest, Hungary). The digital
images were viewed using the 3D Histech Panoramic Viewer (3DHISTECH Ltd., Budapest,
Hungary). TILs were semi-quantitatively assessed following the recommended method of the
2014 International TILs Working Group 7. Each section was first scanned using low magnifi-
cation and the regions of interest located within the invasive tumour borders in the stromal
compartment; around and dispersed in the intervening stroma between carcinoma cells but not
directly contacting tumour cells. TILs around crush artefacts, tumour necrosis, extensive cen-
tral regressive hyalinisation, or DCIS/normal lobules were not considered for quantification.
All mononuclear cells, lymphocytes, histiocytic cells, and plasma cells, if any, were scored and
recorded as a percentage of TILs. The quantity of TILs was evaluated by the percentage of
TILs occupied in the stroma (average TILs; AV-TILs). For further quantification of the pattern
of TILs infiltrate, the presence of areas with dense TILs infiltrate were further determined and
designated as ‘Hotspots-TILs’ (HS-TILs). HS-TILs was defined as a cluster of lymphocytes
7densely containing the highest number of lymphocytes which is typically more than that of the
overall/average stromal TILs. HS-TILs was equal to AV-TILs only in the cases showing no or
occasional scattered lymphocytes or in rare cases showing dense lymphocytic infiltration
throughout the tumour. The highest area of TILs density was considered as the HS and was
introduced to study intra-slide as well as inter-slides TILs heterogeneity. For assessment of
intra-slide heterogeneity, annotation of each digital image was performed by dividing the tu-
mour area into four quadrants using a vertical and horizontal line. AV-TILs and HS-TILs were
assessed in each quadrant separately in addition to the whole slide. All cases were scored in-
dependently by two observers (M. Althobiti and C. Joseph), blinded to histopathological data
and patients’ outcome. The observers were trained by a consultant pathologist (ER). Further,
to test for the intra-observer reproducibility of our scoring system, 50% of the cases were ran-
domly selected and rescored by the same scorer.
STATISTICAL ANALYSIS
Intra-observer agreement was determined using Pearson correlation coefficient whereas inter-
observer agreement was determined using intra-class correlation coefficient. TILs scores were
categorised using a 10% cut-off with scores <10% defined as negative/low whereas cases with
scores ≥10% were defined as positive/high 18. In recurrent tumours, the median percentage of
TILs scores (5%) was used. Positive immunoreactivity for CD3, CD8, CD20, FOXP3, and
CD68 were defined as previously described 13-15, 19. The association between the categorical
groups of TILs density and clinico-pathological parameters were analysed using Chi-square
test. Spearman rank correlation co-efficient was used to assess the relationship between TILs
and immune cell subtypes. Friedman and Kendall’s test was used for testing TILs expression
between four slides (inter-slide heterogeneity) and in four quadrants (intra-slide heterogeneity).
Association with patient outcome was assessed using Kaplan-Meier and log-rank test. Cox
proportional hazards regression models were built for multivariate survival analyses to estimate
8the hazard ratio (HR) of TILs and immune cell subtypes adjusted by other established prog-
nostic factors. A p-value of less than 0.05 (two- tailed) was considered significant in all statis-
tical tests.
9RESULTS
Immune cell subtypes and TILs
In the study cohort, 74.7% of the tumours were ER positive, 59% were PR+ positive and 9.3%
were HER2 positive. To assess specific sub-population of TILs, the expression of lymphocytic
biomarkers; CD3, CD8, CD20, and FOXP3 and macrophage/histiocytic biomarker; CD68 were
evaluated in the whole cohort (n=1,165). Supplementary Table 2 shows the distribution of im-
mune subtypes within different molecular classes. This revealed that the T-lymphocyte popu-
lation, as demonstrated by pan-T (CD3+ cells), was the main component of TILs followed by
macrophages (CD68+ cells), while B-lymphocytes (CD20+ cells), comprised the least com-
mon component. Among T-lymphocytes, the overall contribution of CD8+ cells was more fre-
quent than FOXP3+ cells. Despite the increased number of all immune cells components in
TNBC, the ratio of each subtype appeared similar across the whole series with the CD3+ cell
population being the main contributing component (Figure 1).
Univariate survival analysis demonstrated that high FOXP3+ and CD68+ counts were associ-
ated with shorter BCSS in all BC subtypes (p=0.006 and p<0.001, respectively; Supplementary
Figures 1). However, high CD20+ cells showed a trend toward longer BCSS (p=0.066)
High CD3+ (p=0.021, p=0.011), CD8+ (p=0.017, p=0.012), and CD20+ cells infiltrate
(p=0.037, p=0.045) were associated with longer BCSS and DMFS respectively in TNBC (Sup-
plementary Figures 2A-C). Dense histiocytic CD68+ cells were associated with shorter BCSS
in luminal B tumours (p=0.04). High CD20+ infiltrate was associated with better BCSS in
HER2 positive tumours (p=0.04) (Supplementary Figures 3A&B respectively). Cox-propor-
tional models including patient age, tumour grade, nodal stage and different immune cell sub-
types showed only high CD8+ (p=0.002, HR 0.5, 95%CI 0.3– 0.8) and high CD3+ (p=0.003,
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HR 0.3, 95%CI 0.2– 0.7) lymphocytic infiltrates were independent predictors of improved out-
come in TNBC while CD20+, CD68+ and FOXP3+ cells were not significantly associated with
outcome (supplementary table 3).
TILs morphological heterogeneity
We observed high reproducibility of TILs scoring by the same observer (Pearson correlation
coefficient: 0.93 for AV-TILs and 0.97 for HS-TILs), and between the two observers (intra-
class correlation coefficient: 0.79 for AV-TILs and 0.83 for HS-TILs) and (kappa agreement:
0.825 for AV-TILs and 0.785 for HS-TILs) using the methodology adopted in this study 7.
Inter-observer agreement was determined using intra-class correlation coefficient for the four
slides between the two scorers (0.771 for slide 1, 0.580 for slide 2, 0.682 for slide 3 and
0.910 for slide 4)
The mean, median and range of TILs percent of AV and HS scores in both the primary and
recurrent tumours are displayed in supplementary table 4 A&B.
No significant differences between slides representing various tumour blocks/areas were iden-
tified (inter-slide variation, p=0.251 for AV-TILs and p=0.162 for HS-TILs) (supplementary
Figure 4). Moreover, our result showed that patients with the luminal A tumours were more
homogenous in respect of inter-slide AV-TILs expression than other subtypes. When each slide
was divided into four quadrants and each quadrant scored independently, the variation of TILs
was statistically significant (intra-slide variation, p=0.019 for AV-TILs and p<0.0001 for HS-
TILs). Interestingly, recurrent tumours showed a trend towards lower TILs scores (p=0.052)
and showed homogeneous TILs distribution when compared with their corresponding primary
tumour (Figure 2). AV-TILs was higher in TNBC compared with other BC classes (p<0.001).
Significant multiple correlations between AV-TILs and different immune cell subpopulations
and between the immune cells markers were identified (all p<0.001).
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TILs (AV and HS) in primary BC were positively associated with higher tumour grade
(p<0.001), tumour stages (p=0.038), poor NPI prognostic group (p<0.001), TNBC (p<0.001),
and AR negative phenotypes (p=0.012). No significant association between TILs and patients
age, tumour size, lymph node stage or LVI status was identified (Table 1). TILs (AV and HS)
showed a positive association with the grade in TNBC. Interestingly, within TNBC, AR posi-
tivity was associated with lower scores of TILs (p<0.001). No association was identified be-
tween TILs scores and basal-like phenotype as defined by basal cytokeratin and EGFR 17.
Univariate survival analysis showed no significant association between TILs (AV and HS) and
patient BCSS either in the whole cohort or those with local recurrence.
High AV-TILs showed significant association with longer BCSS in TNBC patients
(p=0.026), where distant metastasis developed in only 91 cases out of 230 cases. However,
61 cases of TNBC showed TILs associated with longer distant metastasis free survival
(p=0.017) (Figure 3). This was not observed in other BC subtype. Notably, survival analysis
between treated and untreated patients (chemotherapy and endocrine therapy) did not show a
significant association. However, in TNBC AV-TILs was a prognostic factor independent of
adjuvant chemotherapy treatment. No significant association between HS-TILs and BCSS or
DMFS was identified in any of BC subtypes.
As AV-TILs was a significant predictor of outcome in TNBC, further analyses were limited to
TNBC. Cox-proportional models including other prognostic parameters including patient age,
tumour grade, and nodal stage showed that AV-TILs was an independent predictor for good
prognosis [p=0.004, HR 0.4, 95% CI 0.2– 0.8). In the model including TILs and various im-
mune cells (CD3, CD8, FOXP3, CD20 and CD68), only AV-TILs showed significant associ-
ation with patient outcome (supplementary Table 5).
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Testing the prognostic power of the combination of positive/negative TILs with high/low im-
mune biomarker was performed, however there was no significant association in all breast
cancer subtypes. Interestingly, in recurrent tumours, there was a significant association be-
tween high AV-TILs density and shorter post-recurrence patient survival (p=0.004) (Figure 4).
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DISCUSSION
There is a growing interest in quantifying and reporting total TILs in BC and their different
subpopulations in clinical practice due to their prognostic and possibly predictive value for
immunotherapies 24, 25. In this study, a large cohort with long-term clinical follow-up was used
to assess different immune cells infiltrate and their expression pattern in BC as well as corre-
lating with patient outcome and tumour progression.
The International TILs Working Group has reported that in most tumours, there is no obvious
inter-slide heterogeneity (i.e. between multiple tissue sections from different tumour blocks of
the same case) in TILs content at the morphological level. However, no robust evidence to
support this observational statement has yet been provided 7. To our knowledge, ours is the
first study to assess TILs heterogeneity utilising multiple tumour tissue blocks from the same
primary tumour and comparing these with their corresponding recurrence. For each sample in
this study, TILs were assessed as average (AV-TILs) and hotspots (HS-TILs) to elaborate upon
TILs distribution in different tumour areas. Our results showed no significant differences in
the overall TILs scores between tumour blocks whether assessed as AV-TILs or HS-TILs, in-
dicating that any full-face H&E breast tumour tissue section is sufficient to evaluate TILs den-
sity within a whole tumour. However, when the analysis was limited to smaller tumour areas
as per different areas of the same slide (intra-slide heterogeneity), the difference in TILs scores
were significant, particularly with regard to hotspots.
The latter finding represents the presence of substantial intra-slide heterogeneity and therefore
underscores the variable nature of immune infiltrate within different tumour cells population.
This is consistent with earlier reports, where CD8, CD3, and CD20 expressing TILs subpopu-
lations in core biopsies were more heterogeneous across the core compared with multiple cores
from the same tumour 26. The variation of CD3, CD8 and CD20; were 30 -33% between the
cores biopsy from same tumour while the higher variation 66-69% was in the same section27.
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Another study reported that spatial heterogeneity of TILs subtypes could play role in patient’s
outcome. For instance, high CD3+ T lymphocytes in invasive margin is associated with disease
free survival in BC, where high total and distance CD8+ T lymphocyte corresponded with
better outcome in BC28. Both assessment methods of TILs; AV-TILs and HS-TILs, were sig-
nificantly associated with other prognostic parameters in the whole cohort 28.
Interestingly, TILs showed lower proportions and were mostly homogenously distributed in
recurrent tumours compared with their corresponding primary tumours. This is consistent with
a previous report where lower expression of TILs in metastatic recurrences of TNBC and HER2
positive BC were observed compared to primary tumours 29. Moreover, significantly shorter
post-recurrence survival was observed in recurrent patients with dense TILs, providing evi-
dence that assessment of TILs in recurrent tumours can be used as a prognostic variable to
predict post-recurrence outcome. Of note, the recurrent tumours included all BC subtypes.
Thus, the inverse association could be explained, at least in part, by the heterogeneity of BC
and the variation of TILs interaction with primary and recurrent tumour as well the different
subtypes.
This study showed that TILs sub-populations were differently expressed in BC tumours where
T-cells, as defined by CD3+ cells, appeared to dominate. This indicates that TILs are a heter-
ogeneous mixture of different immune cell types that are most likely recruited to the tumour
vicinity to perform specific functions 30, 31. Additionally, our data showed that CD3, CD8,
FOXP3, CD20 and CD68 were significantly associated with overall TILs, and TILs were
higher in the more aggressive TNBC subtype than others. It has been reported that TILs as-
sessed in H&E sections are significantly associated with CD20+ and CD45+ in BC32. The high
CD8+ and CD3+ cellular infiltrate showed a good prognosis and independent predictive value
in TNBC regardless of other clinicopathological parameters. These findings are concordant
with the results reported by other studies 15, 33, 34. The higher CD20+ lymphocytes within the
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tumour were associated with better outcome in TNBC and HER2+. This may point to the higher
immunogenicity of TNBC and HER2+ BC than luminal BC due to producing more B-cell
antibodies against the tumour cell; results consistent with those reported by Buisseret and col-
leagues 35. Several subtypes of TNBC with their clinical relevance have been described with
better outcome or treatment responses36. However, there was no significant association be-
tween FOXP3+ and patient outcome in TNBC. In contrast to our observations, Yeong et al
reported that high density of intra tumoral FOXP3+ was associated with longer overall survival
but not with stromal infiltration37 . In our study, lower TILs scores were observed in the AR
positive subclass of TNBC which is considered as prime candidates for anti-androgen and
CDK4/6 inhibition therapies 38, 39. However, no differential expression of TILs or various im-
mune cell subtypes was observed with regard to sub-classification of TNBC into basal-like and
non-basal-like groups 17.
High expression of CD68 was significantly associated with worse outcome in patients with
luminal B tumours, which may explain, at least in part, the distinct roles of TILs sub-population
in different BC subtypes 40. These results also underscore a distinct tumour stromal interactions
in TNBC compared to non-TNBC tumours as evidenced by their different inflammatory mi-
croenvironment. The tumour association macrophage differentiates to active classic (M1) and
alternative (M2) where the latter is associated with growth, angiogenesis, migration and inva-
sion of a diversity of cancers41.
The significant association of AV-TILs with different lymphocyte subtypes and its independent
association with outcome in this study signify the reliability of AV-TILs as assessed on H&E
stained sections for accurate immune cell scoring as a prognostic parameter in BC. CD3 and
CD8 lost their prognostic effect when they were included in the same model. This provides
evidence for the utility of prognostic value of AV-TILs assessment in H&E stained sections,
particularly in TNBC.
16
In conclusion, TILs infiltrate is significantly different between TNBC and non-TNBC with
distinct subpopulations of immune cells in the former. This might explain the different prog-
nostic utility of TILs infiltrate and the immune cells subtypes in BC. Although the International
TILs International Working Group have recognised heterogeneity as an issue, no data is avail-
able to provide any strong guidance. Our result confirms that average TILs assessment using
one representative tumour block can reliably report on TILs infiltrate across a whole breast
tumour. Assessing average TILs score using H&E slides not only provides reproducible and
independent prognostic information in TNBC but is also equivalent to immunohistochemically
defined subpopulations of immune cells. The role of B-lymphocytes and histiocytes in BC
biology and prognosis as well as the association between TILs and the outcome in the recurrent
tumour, warrant further investigation.
17
Legends of the figures
Figure 1 Representative photomicrographs of the expression of immune cell markers (CD3,
CD8, FOXP3, CD20, and CD68)
Figure 2 Representative photomicrographs of the difference between tumour proportions of
TILs infiltrate in the same case for primary (A, B) and its corresponding recurrent tumour (C,
D)
Figure 3: Kaplan Meier survival plots for average TILs % expression in triple negative
breast cancer for A) breast cancer specific survival (BCSS) & B) Distant Metastasis Free Sur-
vival (DMFS)
Figure 4: Kaplan Meier survival plots for TILs % expression in recurrent breast cancer
showing the post-recurrence survival
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Table 1: Associations of tumour infiltrating lymphocytes (Average TILs) and
clinicopathological parameters in breast cancer (n=230)
Parameters Whole cohort
(n=1165)
TILs H&E subgroup (n=230)
N (%) Low TILs
No. (%)
High TILs
No. (%)
2
p-value
Patient Age (Years)
< 50
   ≥ 50 
818(66.0)
421(34.0)
44 (37.9)
31 (27.4)
72 (62.1)
82 (72.6)
2.9
0.091
Tumour size (cm)
< 2
   ≥ 2 
600(48.8)
630(51.2)
44 (28.6)
31 (41.3)
110 (71.4)
44 (58.7)
3.7
0.038
Lympho-vascular Invasion
Negative
Positive
855(69.7)
855(69.7)
52 (34.9)
23 (28.8)
97(65.1)
57(71.3)
0.9
0.344
Tumour Grade
Grade I
Grade II
Grade III
257(19.6)
443(33.7)
612(46.6)
12 (75.0)
19 (55.9)
43 (24.2)
4 (25.0)
15 (44.1)
135 (75.8)
27.3
<0.001
Axillary nodal stage *
Stage I
Stage II
Stage III
897(66.5)
357(26.5)
94(7.0)
53 (37.9)
17 (28.3)
4 (14.3)
87 (62.1)
43 (71.7)
24 (85.7)
6.5
0.038
Nottingham Prognostic Index
Good Prognostic Group
Moderate Prognostic Group
Poor Prognostic Group
187(15.2)
629(51.1)
414(33.7)
9 (15.8)
49 (33.3)
17 (68.0)
48 (84.2)
98 (66.7)
8 (32.0)
21.6
<0.001
Oestrogen Receptor
Negative
Positive
329(25.3)
973(74.7)
36 (21.8)
39 (60.9)
129 (78.2)
25 (39.1)
32.1
<0.001
Progesterone Receptor
Negative
Positive
483(40.6)
708(59.4)
43 (24.2)
32 (62.7)
135 (75.8)
19 (37.3)
26.8
<0.001
HER2 status
Negative
Positive
1063(73.2)
135(9.3)
69 (32.5)
5 (31.3)
143 (67.5)
11 (68.8)
0.1
0.915
Triple negative status
Non-triple negative
Triple negative
1052(83.2)
213(16.8)
41 (55.4)
33 (21.44)
33 (44.6)
121 (78.6)
26.3
<0.001
* Nodal status based on Nottingham system nodal stage (1 for node negative, 2 = 1-3 nodes
positive, and 3 ≥ 4 nodes positive).
Supplementary figures
Supplementary figure 1: Kaplan Meier survival plots (A &B) showing association between
FOXP3+ and CD68+ in and breast cancer specific survival (BCSS)
supplementary figure 2a: Kaplan Meier survival plots showing association between CD3+
lymphocytes’ density in triple negative breast cancer and A) BCSS & B) Distant Metastasis
Free Survival (DMFS)
Supplementary figure 2b: Kaplan Meier survival plots for showing association between
CD8+ lymphocytes’ density in triple negative breast cancer and A) BCSS & B) DMFS.
Supplementary figure 2c: Kaplan Meier survival plots for showing association between
CD20+ lymphocytes density in triple negative breast cancer and A) BCSS & B) DMFS.
Supplementary figure 3: A) Kaplan Meier survival plots showing association between
CD68+ histiocytes’ density in luminal B breast cancer subtype B) CD20+ lymphocytes’
density in HER2+ enriched breast cancer and BCSS.
Supplementary figure 4 shows average TILs & hotspot TILs scores in multiple tumour
blocks. S1, 2, 3 & 4 are sections 1, 2, 3, & 4 from four different tumour blocks

Supplementary Table 1: Antibodies used in immunohistochemistry.
Antibody Clone Dilution Antigen retrieval Source
CD3 SP7 1:100 Microwave in EDTA Vector laboratories
CD8 1A5 1:50 Microwave in citrate Vector laboratories
FOXP3 23A/E7 1:100 Microwave in EDTA Abcam
CD20 L26 1:300 Microwave in citrate Dako
CD68 KP1 1:300 Microwave in citrate Dako
Supplementary Table 2: Mean, median and range, of immune cell subtypes counts/core diameter assessed as absolute number of cells (in the
whole series and in different BC molecular subtypes).
Stromal
immune cell
density/core
diameter
Whole series Luminal A Luminal B HER2 enriched Triple negative
Mean Median Range Mean Median Range Mean Median Range Mean Median Range Mean Median Range
CD3+ 55 33 0-450 34 22 0-258 44 25 0-317 73 51 0-425 93 67 0-450
CD8+ 25 11 0-242 16 8 0-142 22 10 0-317 31 17 0-173 40 23 0-242
FOXP3+ 14 7 0-153 6 2 0-55 11 5 0-68 19 13 0-153 27 21 1-128
CD20+ 13 1 0-415 7 0 0-211 11 1 0-253 22 3 0-415 24 5 0-255
CD68+ 32 24 0-252 18 15 0-150 28 23 1-215 38 32 3-252 51 42 1-225
Supplementary Table 3: Multivariate Cox regression hazard model including other prognostic clinicopathological parameters shows that average
TILs as well as immunohistochemically defined CD3+ or CD8+ T-lymphocytes provided an independent prognostic value; associated with longer
breast cancer specific survival in the subset of triple negative breast cancer.
Variable Hazard ratio 95% Confidence Interval (CI) p- value
Lower Upper
Patient Age 0.7 0.6 4.2 0.169
Tumour Grade 2.9 1.1 3.1 0.134
Node Stage 2.0 0.5 2.2 <0.001
Tumour Size 1.3 0.7 2.3 0.291
TILs-AV 0.4 0.2 0.7 0.004
Patient Age 0.6 0.4 1.0 0.055
Tumour Grade 1.9 0.6 5.8 0.252
Node Stage 1.7 1.2 2.2 <0.001
Tumour Size 1.5 0.9 2.4 0.081
CD8+ 0.4 0.2 0.7 0.002
Patient Age 0.6 0.4 1.0 0.08
Tumour Grade 1.4 0.7 3.2 0.998
Node Stage 1.6 1.2 2.1 0.001
Tumour Size 1.4 0.9 2.3 0.097
CD3+ 0.3 0.1 0.6 0.003
Supplementary table 4A: Mean, median and range of %TILs in primary and their corresponding recurrence in subset of study cohort (n=44)
Supplementary table 4B: Mean, median and range of %TILs in different breast cancer molecular subtype
% of stromal
TILS/tumour
Primary tumour Recurrent tumour
Mean Median Range Mean Median Range
AV-TILs
HS-TILs
22
38
15
28
1-80
1-90
9
13
5
7
1-45
1-60
% of stromal
TILS/tumour
Luminal A Luminal B HER2 enriched Triple negative
Mean Median Range Mean Median Range Mean Median Range Mean Median Range
AV-TILs
AV-TILs
HS-TILs
8
16
5
8
1-40
2-90
12
22
10
12
3-40
3-90
16
33
12
20
5-50
6-90
27
45
25
40
1-85
1-90
Supplementary table 5: Multivariate Cox regression hazard model including average TILs and various immunohistochemically defined immune
cell subtypes shows that average TILs is the only independent prognostic parameter associated with longer breast cancer specific survival in the
subset of triple negative breast cancer
Variable Hazard ratio 95%CI p-valueLower Upper
CD3+ 0.6 0.1 2.8 0.487
CD8+ 0.5 0.2 1.1 0.088
FOXP3+ 1.8 0.5 6.1 0.313
CD20+ 1.1 0.5 2.5 0.724
CD68+ 2.3 0.7 7.5 0.140
AV-TILs 0.3 0.1 0.8 0.023
